PETRA

ASIAWATER 2024 OPENS: CHARTING A COURSE FOR WATER RESILIENCE THROUGH INNOVATION

Retrieved on: 
Tuesday, April 23, 2024
Knowledge, Climate change, IWA, Dato, Kuala Lumpur Convention Centre, KLCC, International Water Association, Exhibition, Energy transition, Water resources, Water, Culture, MWA, Face, Adviser, PETRA, International

KUALA LUMPUR, Malaysia, April 23, 2024 /PRNewswire/ -- ASIAWATER 2024, the region's leading event dedicated to water and wastewater solutions for developing Asia, officially opened its floodgates at the Kuala Lumpur Convention Centre (KLCC) in Malaysia. This marks the start of a three-day expo and forum poised to attract over 20,000 industry professionals from 61 countries, eager to explore cutting-edge solutions that will shape a more sustainable future for water.

Key Points: 
  • Themed "Water Transformation and Climate Change: Innovation for Resilience," the event underscores the urgency of safeguarding our water security in the face of these profound challenges.
  • The event unites industry leaders, experts, and stakeholders to chart a course for a more sustainable water future.
  • Dato' Teo Yen Hua, Advisor of ASIAWATER 2024, emphasised, "ASIAWATER 2024 is a cornerstone event for developing Asia, fostering knowledge exchange, showcasing advancements, and forging partnerships crucial to addressing water challenges.
  • Join ASIAWATER 2024 from 23 – 25 April 2024 at KLCC, Malaysia, and be part of the solution.

ASIAWATER 2024 OPENS: CHARTING A COURSE FOR WATER RESILIENCE THROUGH INNOVATION

Retrieved on: 
Tuesday, April 23, 2024
Knowledge, Climate change, IWA, Dato, Kuala Lumpur Convention Centre, KLCC, International Water Association, Exhibition, Energy transition, Water resources, Water, Culture, MWA, Face, Adviser, PETRA, International

KUALA LUMPUR, Malaysia, April 23, 2024 /PRNewswire/ -- ASIAWATER 2024, the region's leading event dedicated to water and wastewater solutions for developing Asia, officially opened its floodgates at the Kuala Lumpur Convention Centre (KLCC) in Malaysia. This marks the start of a three-day expo and forum poised to attract over 20,000 industry professionals from 61 countries, eager to explore cutting-edge solutions that will shape a more sustainable future for water.

Key Points: 
  • Themed "Water Transformation and Climate Change: Innovation for Resilience," the event underscores the urgency of safeguarding our water security in the face of these profound challenges.
  • The event unites industry leaders, experts, and stakeholders to chart a course for a more sustainable water future.
  • Dato' Teo Yen Hua, Advisor of ASIAWATER 2024, emphasised, "ASIAWATER 2024 is a cornerstone event for developing Asia, fostering knowledge exchange, showcasing advancements, and forging partnerships crucial to addressing water challenges.
  • Join ASIAWATER 2024 from 23 – 25 April 2024 at KLCC, Malaysia, and be part of the solution.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Thursday, April 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Thursday, April 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Fujitsu Network Business Head Moves to North America, Strengthening Market Presence

Retrieved on: 
Monday, April 4, 2022
MIC, LinkedIn, Fujitsu, Audio and Radio Industry Awards, Communication, CEO, Bachelor of Electrical Engineering, ICT, Mizuno, Tokyo University of Science, Software, Industry, Association, Ecosystem, Association of Radio Industries and Businesses, Electricity, PETRA, US, Ministry, ARIB, Solution, Internal affairs, Mobile phone

RICHARDSON, Texas, April 4, 2022 /PRNewswire-PRWeb/ -- Fujitsu Network Communications has announced that Shingo Mizuno, Global Head of the Fujitsu Network Business is transferring his base to the United States, effective April 1. Mizuno also is now acting President and CEO of Fujitsu Network Communications, replacing Doug Moore, who has been appointed CEO of Fujitsu North America.

Key Points: 
  • Shingo Mizuno to continue as Global Head of Network Business, while taking new role leading Fujitsu Network Communications
    RICHARDSON, Texas, April 4, 2022 /PRNewswire-PRWeb/ -- Fujitsu Network Communications has announced that Shingo Mizuno, Global Head of the Fujitsu Network Business is transferring his base to the United States, effective April 1.
  • Mizuno also is now acting President and CEO of Fujitsu Network Communications, replacing Doug Moore, who has been appointed CEO of Fujitsu North America.
  • "To help our customers achieve greater business value, Fujitsu is paving the way to improved digital transformation technologies and open ecosystems."
  • About Fujitsu Network Communications Inc.
    Fujitsu Network Communications, Inc. is a leading provider of digital transformation solutions for network operators, service providers and content providers worldwide.

Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination

Retrieved on: 
Wednesday, December 22, 2021
Tripura Merger Agreement, Technology, Disease, Sale, Meteora, Immunity, Prospectus, Ownership, Private Securities Litigation Reform Act, Acquisition, Forward-looking statement, COVID-19, Special, Revelation, Business architecture, Allergic rhinitis, Degenerative disease, Rhinovirus, GLOBE, Infection, Influenza, Failure, Risk, AXA, Proxy, SEC, PETRA, Severe acute respiratory syndrome coronavirus 2, File, Â, NASDAQ, Respiratory disease, Securities Act of 1933, Therapy, Vaccination, Mergers and acquisitions, RSV, Nasdaq, Form, Name, Institutional Venture Partners, EMA, SAN, Research, FDA, Pharmaceutical industry, Vaccine, Security (finance)

The backstop agreements and forward share purchase agreements with AXA Prime Impact Master Fund, Meteora Capital Partners, LifeSci Venture Partners, and other Petra and Revelation institutional and individual holders, total up to $12 million.

Key Points: 
  • The backstop agreements and forward share purchase agreements with AXA Prime Impact Master Fund, Meteora Capital Partners, LifeSci Venture Partners, and other Petra and Revelation institutional and individual holders, total up to $12 million.
  • These backstop agreements and forward share purchase agreements should ensure the minimum cash condition required of the business combination agreement will be met and provide the post-business combination entity with working capital to fund the continued development of Revelations REVTx-99 product candidate.
  • On December 21, 2021, Petra entered into backstop agreements with AXA Prime Impact Master Fund, LifeSci Venture Partners and other Petra and Revelation institutional, and individual investors (the Backstop Subscribers).
  • Revelation and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Petra in connection with the proposed Business Combination.

Petra Acquisition, Inc. Announces Special Meeting of Stockholders to Approve Business Combination with Revelation Biosciences, Inc.

Retrieved on: 
Thursday, December 16, 2021
Tripura Merger Agreement, Severe acute respiratory syndrome coronavirus 2, Ownership, SAN, Acquisition, Securities Act of 1933, NASDAQ, Risk, Disease, PETRA, Prospectus, Forward-looking statement, Form, FDA, Vaccination, Influenza, EMA, U.S. Securities and Exchange Commission, Eastern Time Zone, Allergic rhinitis, Security (finance), GLOBE, Combined, Rhinovirus, Revelation, Business architecture, Immunity, Nasdaq, COVID-19, SEC, Research, Registration statement, RSV, Failure, Business, Private Securities Litigation Reform Act, Sale, Name, NEW, Degenerative disease, File, Proxy, Mergers and acquisitions, Infection, Technology, Special, Pharmaceutical industry, Auction, Shareholder

NEW YORK and SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ: PAICU, PAIC, & PAICW), (“Petra”) a special purpose acquisition company, today announced that it will hold a Special Meeting of Stockholders (the “Special Meeting”) to vote on the approval of the proposed Business Combination (the “Business Combination”) with Revelation Biosciences, Inc. (“Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease.

Key Points: 
  • Petra common stockholders of record at the close of business on the record date of December 16, 2021 are entitled to vote at the Special Meeting.
  • Petra and Revelation entered into a definitive agreement relating to the Business Combination on August 29, 2021.
  • The Business Combination, if approved by Petras stockholders, is expected to close as soon as practicable following the Special Meeting.
  • Petra stockholders are encouraged to submit their vote as soon as possible to ensure they are represented at the Special Meeting.

Petra Unveils the First Tunneling Technology for Utilities to Bore Through the Hardest Rocks in the World

Retrieved on: 
Thursday, December 9, 2021
Mining, Minerals, Technology, Utilities, Energy, Natural Resources, Hardware, Energy Information Administration, Twitter, Series, Face, Capitalism, Technology, Deep tech, Sewage, Climate change, Economics, Â, Safety, CPO, Microtunneling, CEO, Industry, Bedrock, Geology, EIA, Maintenance, Achievement, Tunnel boring machine, Military geology, Robotics, Directional boring, Tesla, Electricity, Water, Solution, City, Wildfire, HDD, Tunnel, Renewable energy, Petra, DCVC, PETRA, DCVC

Our non-contact method is the next evolution of tunneling and will usher in a new age of undergrounding utilities, said Petra CEO and co-founder Kim Abrams.

Key Points: 
  • Our non-contact method is the next evolution of tunneling and will usher in a new age of undergrounding utilities, said Petra CEO and co-founder Kim Abrams.
  • Petra has developed the first non-contact, thermal-drilling method that can uniquely bore 60-inch diameter micro tunnels through hard rock, making it possible to bore utility tunnels through previously impenetrable geologies.
  • By contrast, Petra is capable of boring a range of diameters between 20-60 inches, dramatically reducing the costs of tunneling.
  • Together, we have created tens of billions of dollars of value, while also making the world a markedly better place.

Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza

Retrieved on: 
Wednesday, December 1, 2021
Special, CCR3, Form, Vaccination, Prospectus, Immunity, Risk, GLOBE, Incidence, Infection, RSV, Influenza, Private Securities Litigation Reform Act, Degenerative disease, Eosinophil, Death, Research, Tripura Merger Agreement, File, T helper cell, Failure, TLR4, Interferon, Sale, Forward-looking statement, Absenteeism, Seroconversion, PETRA, NASDAQ, Business architecture, Mergers and acquisitions, FDA, Rhinovirus, Polyp, Allergic rhinitis, Securities Act of 1933, Safety, Technology, Acquisition, Severe acute respiratory syndrome coronavirus 2, SEC, Proxy, SAN, Business, Revelation, COVID-19, Nasdaq, EMA, Ownership, Name, CDC, MMID, AUC, Respiratory syncytial virus, Disease, Vaccine, Online shopping, Financial services

The viral challenge study is the next necessary step in clinical development of REXTx-99 for the treatment of respiratory viral infections.

Key Points: 
  • The viral challenge study is the next necessary step in clinical development of REXTx-99 for the treatment of respiratory viral infections.
  • The start of our viral challenge study is an important step in bringing a potential new therapy to bear on this problem.
  • The Phase 2b, randomized, double-blind, placebo-controlled study will enroll up to 60 participants.
  • The primary endpoint is to evaluate the efficacy of REVTx-99 in reducing influenza virus load in the upper airways during infection.

Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID™

Retrieved on: 
Monday, November 1, 2021
Disease, Failure, Biotechnology, Influenza, RSV, Prospectus, Acquisition, GLOBE, Research, Tripura Merger Agreement, Name, File, Private Securities Litigation Reform Act, List of life sciences, Medtech, Dentistry, Company, Solution, SAN, Goal, Vaccination, EMA, SEC, Digital health, Severe acute respiratory syndrome coronavirus 2, Immunity, Allergic rhinitis, Â, Nasdaq, Special, Axial, Sale, Mergers and acquisitions, MWA, Form, Degenerative disease, Health, Securities Act of 1933, Technology, Infection, NASDAQ, FDA, PETRA, Forward-looking statement, Collection, Revelation, M&A, Business, Proxy, Ownership, Medical device, Business architecture, Vaccine, Pharmaceutical industry, Online shopping, Financial services

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies and diagnostics for the prevention and treatment of disease, announced today that it has engaged MedWorld Advisors to optimize the value of Revelation’s diagnostic tool, REVID™.

Key Points: 
  • REVID is a rapid, point-of-care immunologic diagnostic device that can be used for the detection of upper respiratory viral infection.
  • The team at MedWorld Advisors has the deep experience and global network needed to optimize value for REVID, and the passion to help companies like Revelation provide solutions to the people who need it.
  • Our team looks forward to helping the Revelation Biosciences team move further along the commercialization journey in order to get REVID to the global population.
  • REVID is a point-of-care immunologic diagnostic device that can be used for detection of upper respiratory viral infection.